Browse result page of TopicalPdb


Please click on the ID to see detailed information about each entry.

The total number entries retrieved from this search are
IDSequenceNameNature of peptide or cargoAssayTissue permeabilityTissue SamplePUBMED ID
1245pGlu-HPThyrotropin-releasing hormone (TRH)It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND)Radioimmunoassay and Liquid Scintillation TechniquePermeability coefficient (Kp)= 18.4*105 cm/h, Cumulative amount= 24.9± 1.7 µg/cm2, Enhancement factor (EF) =3.4Human epidermal membrane10205635
1246pGlu-HPThyrotropin-releasing hormone (TRH)It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND)Radioimmunoassay and Liquid Scintillation TechniquePermeability coefficient (Kp)= 16.6*105 cm/h, Cumulative amount= 18.5± 2.1 µg/cm2, Enhancement factor (EF) =3.1Human epidermal membrane10205635
1247pGlu-HPThyrotropin-releasing hormone (TRH)It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND)Radioimmunoassay and Liquid Scintillation TechniquePermeability coefficient (Kp)= 5.4*105 cm/h, Cumulative amount= 7.8± 1.7 µg/cm2, Enhancement factor (EF) =0Human epidermal membrane10205635
1248pGlu-3-methyl-HPM-TRHAnalogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide.Liquid Scintillation TechniquePermeability coefficient (Kp)= 32.0*105 cm/h, Cumulative amount= 41.5±4.9 µg/cm2, Enhancement factor (EF) =4.7Human epidermal membrane10205635
1249pGlu-3-methyl-HPM-TRHAnalogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide.Liquid Scintillation TechniquePermeability coefficient (Kp)=20.2*105 cm/h, Cumulative amount= 20.4± 3.6µg/cm2, Enhancement factor (EF) =3.0Human epidermal membrane10205635
1250pGlu-3-methyl-HPM-TRHAnalogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide.Liquid Scintillation TechniquePermeability coefficient (Kp)= 6.8*105 cm/h, Cumulative amount= 8.6± 1.0 µg/cm2, Enhancement factor (EF) =0Human epidermal membrane10205635
1251TPRLCarboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide familyPotent pheromonotropic/myotropic activityCockroach Myotropic Bioassay and Pheromonotropic Assay (Topical)~ 23 ng/female, ED50=25pmol, Maximal response=60pmolAfter the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface8844762
1252TPRLCarboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide familyPotent pheromonotropic/myotropic activityCockroach Myotropic Bioassay and Pheromonotropic Assay (Topical)~ 62 ng/female, ED50=25pmol, Maximal response=60pmolAfter the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface8844762
1253TPRLCarboranyl pseudotetrapeptide analogue of the insect pyrokinin/PBAN neuropeptide familyPotent pheromonotropic/myotropic activityCockroach Myotropic Bioassay and Pheromonotropic Assay (Topical)~ 70 ng/female, ED50=25pmol, Maximal response=60pmolAfter the scales were removed, 1µl of peptide solution was applied to the surface of the cuticle and smoothed evenly over the prepared surface8844762
1254VTHRLAGLLSRSGGM
VKSNFVPTNVGSKAF
CGRP receptor antagonist CGRP(8-37)Regulation of blood flow, modulation of inflammation, and tissue remodellingPhotographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test.Effect of the CGRP-receptor antagonist CGRP(8-37)(~24.5 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~36.5 mm2).The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats.8584255
1255VTHRLAGLLSRSGGM
VKSNFVPTNVGSKAF
CGRP receptor antagonist CGRP(8-37)Regulation of blood flow, modulation of inflammation, and tissue remodellingPhotographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test.Effect of the CGRP-receptor antagonist CGRP(8-37)(~17 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~25 mm2).The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats.8584255
1256VTHRLAGLLSRSGGM
VKSNFVPTNVGSKAF
CGRP receptor antagonist CGRP(8-37)Regulation of blood flow, modulation of inflammation, and tissue remodellingPhotographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test.Effect of the CGRP-receptor antagonist CGRP(8-37)(~13 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~16.5 mm2).The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats.8584255
1257VTHRLAGLLSRSGGM
VKSNFVPTNVGSKAF
CGRP receptor antagonist CGRP(8-37)Regulation of blood flow, modulation of inflammation, and tissue remodellingPhotographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test.Effect of the CGRP-receptor antagonist CGRP(8-37)(~12 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~14 mm2).The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats.8584255
1258VTHRLAGLLSRSGGM
VKSNFVPTNVGSKAF
CGRP receptor antagonist CGRP(8-37)Regulation of blood flow, modulation of inflammation, and tissue remodellingPhotographed both hind paws using a micro-computer imaging device(MCID)-assessed analysis system. Immunostaining. Mann-Whitney U-test.Effect of the CGRP-receptor antagonist CGRP(8-37)(~7 mm2) on the necrotic area in UV-damaged skin of the rat hindpaw compared to solvent applications(~13.5 mm2).The dorsum of both hind paws were irradiated of male Sprague-Dawley (SD) rats.8584255
1262KRPPGFSPFRKallidinPotent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients.Painful sensation assessed in a visual analogue scale(VAS)Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~10.7(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value.Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex8443036
1263KRPPGFSPFRKallidinPotent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients.Painful sensation assessed in a visual analogue scale(VAS)Pain response obtained in nostrils after capsaicin vehicle pretreatment: ~22(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value.Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex8443036
1264KRPPGFSPFRKallidinPotent inflammatory mediators produced during acute and chronic inflammation.They are released at high nanomolar concentrations into the tear-film of ocular allergic patients.Painful sensation assessed in a visual analogue scale(VAS)Pain response obtained in nostrils after capsaicin pretreatment((50 nmol in 50 µl, everyday for 5-7 days): ~20(VAS value), the intensity of the sensation experienced with a single dose of capsaicin was considered the maximum value (i.e. 100) on the analogue scale, and all successive responses were scored in relation to this value.Solution was applied by a micropipette into the nostril of thirty-four healthy volunteers of either sex8443036
1295HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.03)/Treated(1.72 ± 0.20), PGE2 levels(ng/ear)=Untreated(0)/Treated(83.2 ± 2.8), LTB4 levels(ng/ear)=Untreated(0)/Treated(15.2 ± 1.2)Ear(auditory pinna) of male Swiss Webster mice7646536
1296HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.03)/Treated(1.73 ± 0.13), PGE2 levels(ng/ear)=Untreated(0)/Treated(79.2 ± 3.1), LTB4 levels(ng/ear)=Untreated(0)/Treated(17.6 ± 1.3)Ear(auditory pinna) of male Swiss Webster mice7646536
1297HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.03)/Treated(1.68 ± 0.21), PGE2 levels(ng/ear)=Untreated(0)/Treated(80.1 ± 3.2), LTB4 levels(ng/ear)=Untreated(0)/Treated(18.1 ± 2.2)Ear(auditory pinna) of male Swiss Webster mice7646536
1298HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.02)/Treated(48.2 ± 3.2), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(39.1 ± 3.1), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(381 ± 31), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(893 ± 161)Ear(auditory pinna) of male Swiss Webster mice7646536
1299HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.02)/Treated(42.7 ± 3.1), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(30.9 ± 2.9), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(Not defined), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(697 ± 131)Ear(auditory pinna) of male Swiss Webster mice7646536
1300HDMNKVLDLNonapeptide P2 or AF-2Showed an anti-inflammatory effect in carrageenan-induced rat paw oedema, they inhibit pancreatic and Naja naja PLA2 in vitro and acute inflammatory processes induced by carrageenan or phorbol esters when administered locally or parenterally.MPO and NAG assaysMPO levels(mU/ear)=Untreated(0.02)/Treated(38.2 ± 2.5), NAG levels(mU/ear)=Untreated(23.1 ± 1.1)/Treated(27.1 ± 2.6), 6-keto-PGF1α(pg/ear)=Untreated(198 ± 22)/Treated(254 ± 26), LTB4 levels(pg/ear)=Untreated(0.30)/Treated(523 ± 128)Ear(auditory pinna) of male Swiss Webster mice7646536
1393TCapsaicinRepeated capsaicin applications are assumed to cause desensitization of the nasal mucosa and a decreased secretory responseImmunocytochemistry, electron microscopyThe number of goblet cells was increased in the nasal region. CGRP-Iike activity was decreased in biopsies taken from the test sides of the paranasal sinuses when compared to control.Nasal mucosa of New Zealand White rabbits8737771
1394RPPGFSPFRBradykininSmall endogenous peptide mediators formed de novo at sites of tissue damage where it has important actions that contribute to the acute inflammatory response.Evan's blue dyeInstillation of bradykinin increased extravasation of Evans blue dye to 93.5±7.5 ng/ml from baseline 8.54±0.93 ng/mlNasal mucosa of guinea pigs8719791
1397Botulinum neurotoxin A light chain (PFVNKQF
NYKDPVNGVDIAYIKIPN
AGQMQPVKAFKIHNKI
WVIPERDTFTNPEEGD
LNPPPEAKQVPVSYY
DSTYLSTDNEKDNYLK
GVTKLFERIYSTDLGR
MLLTSIVRGIPFWGG
STIDTELKVIDTNCIN
VIQPDGSYRSEE
LNLVIIGPSADIIQFE
CKSFGHEVLNLTRNGY
GSTQYIRFSPDFT
FGFEESLEVDTNPLL
Botulinum toxin type APotent inhibitor of cholinergic motor nerves.Weights of the nasal secretion were collected and compared.Topically applied botulinum toxin reduced neurally evoked rhinorrhea by an average of 41%.Nasal cavity of male mongrel dogs7700663
1501DF-Me-Phe-GLMSenktideNK3 tachykinin receptor agonist. Causes direct excitation of dopamine neurons; enhances dopaminergic function. Induces locomotor activity.RadioimmunoassayThe mean maximum pupillary constriction observed with senktide (25 mg, i.v.) was 4.25+0.25 mm.Eye of rabbit9351503